A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites (2019)
Attributed to:
CHARACTERISING KYNURENINE 3-MONOOXYGENASE (KMO) AS A THERAPEUTIC TARGET FOR HUNTINGTON'S DISEASE
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s42003-019-0520-5
PubMed Identifier: 31925123
Publication URI: http://europepmc.org/abstract/MED/31925123
Type: Journal Article/Review
Parent Publication: Communications Biology
Issue: 1
ISSN: 2399-3642